Regeneron stock costs EUR 658.15 at a P/ E of 18.2

Published on 10/08/2026 at 20:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock sits at EUR 658.15 on October 8, 2026, versus EUR 662.85. P/E is 18.2 and market cap is USD 76.0 billion.

Key points in brief

Regeneron stock was trading at EUR 658.15 at Lang & Schwarz on October 8, 2026, down 0.71 percent versus EUR 662.85.
The Nasdaq-listed stock was last at USD 737.83 at 2:01 p.m. ET, down 0.58 percent in the same session.
Regeneron's market capitalization was USD 76.0 billion and its P/E ratio was 18.2.
RBC raised its target from USD 737.00 to USD 810.00 while keeping a Sector Perform rating.
Regeneron is scheduled to report third-quarter 2026 results on October 30, 2026.

Makroaufnahme einer transparenten Antikörper-Proteinstruktur in Blau- und Weißtönen — Regeneron Pharma US75886F1075 fokussiert eine detailreiche Makroaufnahme einer transparenten Antikörper-Proteinstruktur mit feinen Lichtreflexen, Illustration mit AI erstellt.

Regeneron (ISIN US75886F1075) was trading at EUR 658.15 at Lang & Schwarz on October 8, 2026 at 8:00 p.m. CEST, down 0.71 percent versus the prior close of EUR 662.85. The move places the euro quote below the previous session while the US listing remains the key valuation reference for global investors.

US quote remains below yearly high

Regeneron's Nasdaq-listed shares were last at USD 737.83 on October 8, 2026 at 2:01 p.m. ET, down 0.58 percent from the previous US close. The listing and ticker REGN are identified in Regeneron's investor release.

The same quote carried a 52-week range of USD 541.00 to USD 859.34. At USD 737.83, Regeneron's stock stood 14.14 percent below the 52-week high, calculated from the Nasdaq quote and its high.

Valuation and analyst target

Regeneron's market capitalization was USD 76.0 billion, while its P/E ratio was 18.2 as of October 8, 2026. The valuation sits alongside a biotechnology business focused on developing and commercializing medicines for serious diseases.

MarketBeat reported on October 8, 2026 that Royal Bank of Canada raised its Regeneron target from USD 737.00 to USD 810.00 and retained a Sector Perform rating. The target is 9.77 percent above the USD 737.83 Nasdaq price.

Comparison with peers

Regeneron: minus 0.58 percent, P/E 18.2, market capitalization USD 76.0 billion.

Amgen (NASDAQ, USD): minus 1.64 percent, P/E 25.3, market capitalization USD 219.3 billion.

Vertex Pharmaceuticals (NASDAQ, USD): minus 0.28 percent, P/E 29.4, market capitalization USD 128.0 billion.

October 30 results date

Regeneron announced on September 24, 2026 that it will report third-quarter 2026 financial and operating results before US markets open on October 30, 2026, followed by a conference call at 8:30 a.m. ET. The date gives the valuation figures a clear next reporting milestone.

Regeneron price and market data

Regeneron's euro quote was EUR 658.15 at Lang & Schwarz on October 8, 2026 at 8:00 p.m. CEST, with a minus 0.71 percent change versus the EUR 662.85 prior close. The US quote was USD 737.83 at 2:01 p.m. ET, and the 52-week high stood at USD 859.34.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.